PureTech Health 的股价暴跌 15.2%，但一家研究公司维持“买入”建议。 PureTech Health's stock plunges 15.2%, yet a research firm maintains a "buy" recommendation.

周二,PureTech Health的股票下跌15.2%,至GBX 117.20 (1.49美元),交易量升至4276万股,较日均值156万股大幅上升. PureTech Health's stock dropped 15.2% to GBX 117.20 ($1.49) on Tuesday, with trading volume surging to 42.76 million shares, a significant rise from the daily average of 1.56 million. 一家金融研究公司重申“买入”评级为455英镑(5.79美元)的目标价格。 Despite this fall, a financial research firm reiterates a "buy" rating with a GBX 455 ($5.79) target price. 纯科技保健专门研制治疗与神经、肠胃和免疫系统有关的疾病的药物。 PureTech Health specializes in developing drugs for diseases linked to the nervous, gastrointestinal, and immune systems.